• 11/11/2024

Two Is Better Than One in the Alzheimer’s Market

Wall Street Journal

The approval of Eli Lilly’s Alzheimer’s drug donanemab could help build momentum for Biogen’s struggling drug Leqembi.

https://www.wsj.com/articles/two-is-better-than-one-in-the-alzheimers-market-2b2e6aca